Arrowhead Pharmaceuticals, Inc.
ARWR
Price:
$19.75
Market Cap:
$2.46B
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channe...[Read more]
Industry
Biotechnology
IPO Date
1993-12-16
Stock Exchange
NASDAQ
Ticker
ARWR
PE Ratio
[-3.95]
ROE
[-206.69%]
Current Ratio
[6.74]
Dividend Yield
[0%]
Enterprise Value
[2.87B]
Dividend History
The ROE as of December 2024 (TTM) for Arrowhead Pharmaceuticals, Inc. (ARWR) is -206.69%
According to Arrowhead Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is -206.69%. This represents a change of 227.61% compared to the average of -63.09% of the last 4 quarters.
Arrowhead Pharmaceuticals, Inc. (ARWR) Historical ROE (quarterly & annually)
How has ARWR ROE performed in the past?
The mean historical ROE of Arrowhead Pharmaceuticals, Inc. over the last ten years is -85.85%. The current -206.69% ROE has changed 140.76% with respect to the historical average. Over the past ten years (40 quarters), ARWR's ROE was at its highest in in the March 2019 quarter at 11.88%. The ROE was at its lowest in in the September 2024 quarter at -91.96%.
Average
-85.85%
Median
-66.25%
Minimum
-323.27%
Maximum
27.79%
Arrowhead Pharmaceuticals, Inc. (ARWR) ROE by Quarter and Year
Discovering the peaks and valleys of Arrowhead Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 383.47%
Maximum Annual ROE = 27.79%
Minimum Annual Increase = -165.89%
Minimum Annual ROE = -323.27%
| Year | ROE | Change |
|---|---|---|
| 2024 | -323.27% | 327.32% |
| 2023 | -75.65% | -54.58% |
| 2022 | -166.57% | 383.47% |
| 2021 | -34.45% | 88.16% |
| 2020 | -18.31% | -165.89% |
| 2019 | 27.79% | -148.89% |
| 2018 | -56.84% | 34.61% |
| 2017 | -42.22% | -50.62% |
| 2016 | -85.50% | 2.46% |
| 2015 | -83.45% | 137.04% |
Arrowhead Pharmaceuticals, Inc. (ARWR) Average ROE
How has ARWR ROE performed in the past?
The current ROE of Arrowhead Pharmaceuticals, Inc. (ARWR) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-188.50%
5-year avg
-123.65%
10-year avg
-85.85%
Arrowhead Pharmaceuticals, Inc. (ARWR) ROE vs. Peers
How is ARWR’s ROE compared to its peers?
Arrowhead Pharmaceuticals, Inc.’s ROE is greater than Wave Life Sciences Ltd. (-251.35%), greater than CytomX Therapeutics, Inc. (-41.34%), greater than Assembly Biosciences, Inc. (-121.46%), greater than Neoleukin Therapeutics, Inc. (-8.54%), less than BioMarin Pharmaceutical Inc. (6.22%), less than Incyte Corporation (0.78%), greater than Ionis Pharmaceuticals, Inc. (-89.18%), greater than Apellis Pharmaceuticals, Inc. (-103.92%), greater than ProQR Therapeutics N.V. (-71.11%), greater than Annexon, Inc. (-38.99%), greater than Day One Biopharmaceuticals, Inc. (-22.40%), greater than Terns Pharmaceuticals, Inc. (-32.76%), greater than Mirati Therapeutics, Inc. (-40.45%), greater than Amylyx Pharmaceuticals, Inc. (-85.39%), greater than IVERIC bio, Inc. (-39.26%), greater than Blueprint Medicines Corporation (-47.66%), greater than Karuna Therapeutics, Inc. (-25.23%),
| Company | ROE | Market cap |
|---|---|---|
| -251.35% | $2.00B | |
| -41.34% | $85.30M | |
| -121.46% | $94.84M | |
| -8.54% | $8.20M | |
| 6.22% | $12.63B | |
| 0.78% | $13.45B | |
| -89.18% | $5.70B | |
| -103.92% | $4.13B | |
| -71.11% | $275.55M | |
| -38.99% | $562.82M | |
| -22.40% | $1.28B | |
| -32.76% | $503.69M | |
| -40.45% | $4.12B | |
| -85.39% | $278.99M | |
| -39.26% | $5.51B | |
| -47.66% | $5.74B | |
| -25.23% | $12.60B |
Build a custom stock screener for Arrowhead Pharmaceuticals, Inc. (ARWR) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Arrowhead Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Arrowhead Pharmaceuticals, Inc. (ARWR) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Arrowhead Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Arrowhead Pharmaceuticals, Inc.'s ROE?
How is the ROE calculated for Arrowhead Pharmaceuticals, Inc. (ARWR)?
What is the highest ROE for Arrowhead Pharmaceuticals, Inc. (ARWR)?
What is the 3-year average ROE for Arrowhead Pharmaceuticals, Inc. (ARWR)?
What is the 5-year average ROE for Arrowhead Pharmaceuticals, Inc. (ARWR)?
How does the current ROE for Arrowhead Pharmaceuticals, Inc. (ARWR) compare to its historical average?